The Impact of Endograft Selection on Outcomes Following Treatment Outside of Instructions for Use (IFU) in Endovascular Abdominal Aortic Aneurysm Repair (EVAR)


Vascular and Endovascular Surgery, Royal Perth Hospital, Perth, Australia; Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland; Medicine, University of Medicine and Health Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland; Curtin Medical School, Faculty of Health Sciences, Curtin University, Perth, Australia; Medicine, University of Western Australia, Perth, Australia; Vascular and Endovascular Surgery, University of Western Australia, Perth, Australia

Corresponding author: Bibombe P. Mwipatayi, patrice@bibombe.com

Abstract

Background

Endovascular aneurysm repair (EVAR) has become the treatment modality of choice in patients with abdominal aortic aneurysms. This has resulted in endograft utilization within instructions for use (IFU) and in cases with proximal neck anatomy outside of IFU.

Purpose

To identify whether graft selection influences outcomes following EVAR outside of IFU.

Methodology

A retrospective analysis was conducted from previously published data for 636 patients, collated from the Endurant Stent Graft Natural Selection Global Post-Market Registry (ENGAGE) and the Global Registry for Endovascular Aortic Treatment (GREAT). Patients were recruited into the ENGAGE registry between 2009 and 2011 and into the GREAT registry between August 2010 and October 2016. In ENGAGE, they received the Medtronic Endurant stent graft (Medtronic Vascular Inc, Dublin, Ireland) for infrarenal AAA repair while patients analyzed in GREAT received the Gore Excluder stent-graft (W. L. Gore & Associates, Flagstaff, Arizona). Analyses were performed to evaluate all-cause mortality, aneurysm-related mortality, endoleak occurrence, and surgical reintervention rates between the two cohorts.

Results

Of the 636 patients, 225 were from ENGAGE (mean age 73 years) and 411 were from GREAT (mean age 75 years). 17.8% were treated outside of IFU in the ENGAGE registry, while 12.4% were treated outside IFU in the GREAT cohort. Five-year freedom from all-cause mortality was similar in both cohorts (65.6% vs. 63.8%). The rate of type IA endoleak development was lower in the Excluder cohort, although this may have been impacted by the fact that only endoleaks that underwent reintervention were recorded within GREAT analysis (Endurant 10.6% vs. Excluder 7.0%). The reintervention rate was 16% at five years following the Endurant aortic graft while it was 13.3% at five years with the Excluder.

Conclusion

Treatment outside of IFU, be it with a suprarenal or an infrarenal fixation device, is associated with worse outcomes. This analysis reinforces the importance of the consideration of either fenestrated or open repair in those aneurysms that fail to satisfy IFU while endovascular repair in such a setting should be reserved as a last resort strategy.

Categories: Cardiac/Thoracic/Vascular Surgery, Medical Education, Quality Improvement
Keywords: abdominal aortic aneurysm, endovascular repair, instructions for use, endoleak, mortality

Introduction

Endovascular aneurysm repair (EVAR) has become the predominant treatment modality for abdominal aortic aneurysms (AAAs) since its introduction over 20 years ago [1]. The change in management was promoted by several short-term benefits, including reduced hospital stay, a swift return to independent living, and low early overall mortality as compared to open aortic repair (OAR) [2–4]. However, when comparing EVAR to
OAR, the mid- to long-term outcomes did not convey a similar advantage [5]. Factors such as stent migration or endoleaks appeared to be the most culpable agents, with the development of subsequent aneurysm repressurization and rupture [6-7].

In response to these issues, graft manufacturers sought to advance the technology and examine risk factors for the development of endoleaks in an attempt to prevent future complications. This led to further development of the ‘instructions for use’ (IFU) criteria. These are a specific set of criteria, provided by the manufacturers, which describe particular aneurysm morphology that should be satisfied to ensure the safe and appropriate utilization of endoprostheses in the correct environment. Criteria vary between grafts, with significant differences noted in those stents involving suprarenal fixation as compared to infrarenal fixation. The IFU generally incorporate factors such as a minimum aortic neck diameter, a minimum aortic neck length, and a maximum aortic neck angulation.

Two of the most widely utilized endoprostheses are the Endurant (Medtronic Vascular Inc, Dublin, Ireland), and the Excluder (W. L. Gore & Associates, Flagstaff, Arizona). Each device has different accepted thresholds for these morphologic features as expressed in their instructions for use (IFU) [8]. The variation in thresholds for device application is likely impacted by the site of proximal stent fixation; Endurant is a suprarenal device as compared to Excluder, an infrarenal device.

The ongoing technological advancements in endograft design and delivery have resulted in a propensity to utilize these stents outside of IFU. The aim of this study is to assess whether graft selection, comparing a suprarenal device and an infrarenal device, influences outcomes following endoluminal AAA repair outside of the IFU.

**Materials And Methods**

**Data source**

Previously published data were obtained and subsequently collated from two sources; the Endurant Stent Graft Natural Selection Global post-market registry (ENGAGE) and the Global Registry for Endovascular Aortic Treatment (GREAT) [9-10].

ENGAGE (Clinicaltrials.gov identifier, NCT00870051) was designed to augment the knowledge base about endovascular aortic aneurysm repair in a real-world population implanted with the Medtronic stent graft system (Endurant) [9]. Patient enrollment in the ENGAGE registry occurred between 2009 and 2011, with a follow-up duration of 10 years. A total of 1,265 patients from 79 international centers were enrolled with minimal inclusion criteria. Selected exclusion criteria included the probability of non-adherence to follow-up requirements and concurrent participation in another trial that might confound results [9]. Data on outcomes following five years of follow-up were utilized within this analysis.

GREAT (Clinicaltrials.gov identifier, NCT01658787) was designed for the collection of data on the management of serious adverse events and follow-up patterns after the implantation of all Gore® aortic endografts (W.L. Gore Associates) [10]. Patient enrollment in the GREAT registry occurred between August 2010 and October 2016. Over 5,000 patients from 114 international centers were enrolled, with broad inclusion criteria and minimal exclusion criteria, reflecting the real-world use of devices, with a follow-up duration of 10 years [10]. Data on outcomes following five years of follow-up were utilized within this analysis.

**Endoluminal prosthesis**

The Endurant endograft, available since 2008, has a two-piece design with a nitinol M-shaped stent skeleton, which is covered with polyester fabric. Proximal fixation is augmented by a suprarenal stent with anchoring pins. The Endurant II was introduced in December 2011 and differed from its predecessor regarding additional radiopaque markers and reduction in the delivery system profile. A later design (the Endurant IIs) included a three-piece design, although this was only made available in 2014. It is not included in this analysis, as inclusion in the ENGAGE registry ended in 2011 [8].

The Excluder endoprosthesis is a modular bifurcated system that has been available since 1997. The main body features eight nitinol anchors for infrarenal fixation while the endografts’ nitinol stent frame is covered by polytetrafluoroethylene (PTFE). In 2004, a structural change to the device was made with the addition of a low permeability expanded PTFE sleeve to the graft composition, owing to high rates of sac growth with the original device. In 2010, the C5 Delivery System appeared, but no graft modifications were made [8].

The Endurant is suitable for infra-renal necks ranging from 19-32 mm, allowing the treatment of infrarenal necks ≥ 10 mm in length if the infrarenal angulation is ≤ 60° and the suprarenal angulation is ≤ 45°. It is also suitable for a neck length of ≥ 15 mm with an infrarenal angulation of ≤ 75° and a suprarenal angulation of ≤ 60°. The Excluder is more conservative and is suitable for infra-renal necks ranging from 19-29 mm in...
diameter and ≥ 15 mm in length, with an infrarenal angulation of ≤ 60° [8].

**Inclusion criteria**

All patients who underwent EVAR for AAA outside of the IFU in the two aforementioned databases were included for analysis. In the ENGAGE registry, IFU recommended an adequate iliac or femoral access vessel morphology compatible with vascular access of the graft to the aorta; proximal aortic neck length of >10 mm with insignificant calcification and thrombus and <60° of infrarenal and <45° of suprarenal angulation or a proximal neck length of 15 mm or greater with insignificant calcification and thrombus with <75° of infrarenal and <60° of suprarenal angulation; distal fixation length of >15 mm or more; aortic neck diameters with a range of 19 to 32 mm; and iliac diameters with a range of 8 to 25 mm. If these criteria were not achieved, aneurysms were deemed as being treated outside of IFU. In comparison, patients within the GREAT registry were deemed to have been treated outside of IFU if the proximal neck length was <15 mm or the infrarenal neck angle was >60°. Outcomes between both groups were assessed according to all-cause mortality, aneurysm-related mortality (ARM), all reinterventions, any endoleak, type Ia endoleak, conversions to open repair, and aneurysm rupture.

**Statistical analysis**

A retrospective analysis of prospectively recorded data from ENGAGE and GREAT was performed. Categorical variables are presented as frequencies with percentages. Continuous variables are presented as mean +/- standard deviation or as median and interquartile range (IQR). The x² or Fisher exact tests were used for categorical variables, depending on sample size. P-values < 0.05 are considered significant. All statistics were performed using SAS software (SAS Institute, Cary, NC).

**Results**

**Baseline demographics and AAA characteristics**

Across the two studies, a total of 636 patients underwent EVAR for AAA outside of IFU. ENGAGE had 225 cases (responsible for 17.8% of cases included in the previously published analysis) while GREAT had 411 cases (12.4% of the total cohort).

Baseline demographics and anatomic aneurysm characteristics for both cohorts are outlined in Table 1. The mean age was 75 (SD 7.7) years for those treated outside of IFU within ENGAGE while it was 74.9 (SD 7.8) years for those treated outside of IFU in the GREAT registry. Maximum aortic aneurysm diameter was greatest in those treated outside of IFU within the GREAT registry (61.2 mm (SD 14.1)) as compared to ENGAGE (60.7 mm (SD 14.5)). Proximal aortic neck length was found to be shorter in those treated with the Excluder stent-graft as compared to the Endurant device (2.2 cm (SD 1.6) vs. 2.5 cm (SD 1.5)). Additionally, infrarenal neck angulation was greatest in the GREAT registry when measured against ENGAGE (60.8° (SD 29.7) vs. 46.5° (SD 32.3)).

<table>
<thead>
<tr>
<th></th>
<th>Endurant</th>
<th>Excluder</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline characteristics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Out of IFU (n = 225)</td>
<td>Within IFU (n = 1038)</td>
<td>p-value</td>
</tr>
<tr>
<td>Age (years)</td>
<td>73 (7.7)</td>
<td>73 (8.2)</td>
</tr>
<tr>
<td>Male</td>
<td>182 (80.9)</td>
<td>948 (91.3)</td>
</tr>
</tbody>
</table>

| **Anatomical characteristics** |          |          |
| Maximum diameter of the aneurysm (mm) | 60.7 (14.5) | 60.2 (11) | .675 |
| Proximal aortic neck length (cm) | 2.5 (1.5) | 2.7 (1.2) | .025 |
| Infrarenal neck angle (degrees) | 46.5 (32.3) | 26.9 (19.9) | < .001 |

<table>
<thead>
<tr>
<th></th>
<th>Out of IFU (n = 411)</th>
<th>Within IFU (n = 2913)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>74.9 (7.8)</td>
<td>73.2 (8.4)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Male</td>
<td>307 (74.7)</td>
<td>2549 (87.5)</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>

**TABLE 1: Baseline demographics and anatomic aneurysm characteristics for both cohorts**

**Outcomes**

*Mortality, Rupture, and Conversion*
Table 2 lists the outcomes. The freedom from all-cause mortality at five years was slightly greater in those treated with the Endurant device (ENGAGE 65.6% vs. GREAT 63.8%). Freedom from aneurysm-related mortality across the same period was 97.2% in the ENGAGE registry while it was 96.2% within the GREAT cohort. The five-year freedom from sac-related rupture was 98.8% in ENGAGE while the requirement for conversion to open repair was 0.4%. Both of these outcomes were not commented upon within the GREAT analysis.

<table>
<thead>
<tr>
<th></th>
<th>ENGAGE</th>
<th>GREAT</th>
<th>P-value</th>
<th>ENGAGE</th>
<th>GREAT</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Out of IFU, %</td>
<td>Within IFU, %</td>
<td></td>
<td>Out of IFU, %</td>
<td>Within IFU, %</td>
<td></td>
</tr>
<tr>
<td>Freedom from all-cause mortality (%)</td>
<td>65.6</td>
<td>67.7</td>
<td>.6</td>
<td>63.8</td>
<td>72.5</td>
<td>.002</td>
</tr>
<tr>
<td>Freedom from aneurysm-related mortality (%)</td>
<td>97.2</td>
<td>97.9</td>
<td>.39</td>
<td>96.2</td>
<td>98.9</td>
<td>.002</td>
</tr>
<tr>
<td>Any endoleak</td>
<td>35.9</td>
<td>30.5</td>
<td>.30</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Type Ia</td>
<td>10.6</td>
<td>3.3</td>
<td>&lt; .001</td>
<td>7.0</td>
<td>1.2</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Conversion to open</td>
<td>0.4</td>
<td>2.4</td>
<td>.16</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>5-year freedom from sac rupture</td>
<td>98.8</td>
<td>98.5</td>
<td>.87</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Secondary reintervention</td>
<td>16.0</td>
<td>16.0</td>
<td>n/a</td>
<td>13.3</td>
<td>9.7</td>
<td>.02</td>
</tr>
</tbody>
</table>

**TABLE 2: Postoperative outcomes at five years**

ENGAGE: Endurant Stent Graft Natural Selection Global Post-Market Registry; GREAT: Global Registry for Endovascular Aortic Treatment; IFU: instructions for use

(n/a: not available as assessed analysis did not provide noted endpoint)

Endoleaks and Secondary Procedures

The five-year rate of any endoleak development was assessed for the ENGAGE registry although it was not addressed in the GREAT analysis. This occurred in 35.9% of those treated with the Endurant device. The rate of Ia endoleak development in these two cohorts of patients (treated outside of IFU) was slightly higher with the Endurant device (ENGAGE 10.6% vs. GREAT 7.0%) although this may have been impacted by the fact that only endoleaks that underwent reintervention were recorded within the GREAT registry. Despite the high rate of any endoleak development in the ENGAGE registry, reintervention was relatively similar between the two cohorts (ENGAGE 16% vs. GREAT 13.3%).

Discussion

This study demonstrates that a significant proportion of patients are undergoing endovascular management of AAA despite failing to satisfy the manufacturer’s designated IFU. A multitude of factors are responsible for this, including a lack of regulatory oversight with an increasingly aggressive interventional approach from clinicians. This trend could be attributed to previous data highlighting relatively similar long-term outcomes between those treated endovascularly as compared to OAR although the significantly higher reintervention rate after EVAR must be considered [11-12].

The successful endovascular treatment of an abdominal aortic aneurysm requires the achievement of the exclusion of blood flow to the aneurysm sac with subsequent depressurization of the aneurysmal wall [13]. Previously, aortic neck anatomy has been highlighted as the greatest single predictor of successful intervention [14]. This included factors such as a short aortic neck and a sizeable degree of aortic neck angulation [14]. These features have been well-recognized as risk factors for long-term complications following EVAR, with higher rates of type Ia endoleak development as well as reintervention [15]. They have formed the basis for the IFU for the commercially available grafts. Despite these well-recognized anatomical features, 15.2% (636/4587) of patients across both the ENGAGE and GREAT cohorts underwent treatment outside of IFU.

The newer generation endografts have likely encouraged this trend toward intervention in hostile aortic neck anatomy. The constant development in technology, with the introduction of lower-profile stent-grafts, as well as more liberal IFU, has likely increased the proportion of AAA being managed endovascularly. Despite these noted advancements, stent grafts continue to be utilized outside of IFU as highlighted by this
study. This is likely influenced by an increasingly aging and co-morbid population who are likely unsuitable
for major open aortic repair. In the absence of alternative options, it seems clinicians are turning to EVAR
despite the noted long-term pitfalls of recurrent reinterventions and their associated morbidity.

The present study demonstrates that freedom from all-cause mortality at five years was slightly higher in
patients treated with the Endurant device (Medtronic) as compared to the Excluder device (Gore) (65.6% vs.
63.8%). This reflects previously published data that promoted the utilization of active suprarenal fixation,
with devices such as the Endurant, in cases with hostile aortic neck anatomy [16]. However, this is not an all-
comprehensive analysis with certain features, such as wide aortic neck diameter, shown to negatively impact
outcomes [16]. Freedom from aneurysm-related mortality following the utilization of the Endurant stent
graft was 97.2% in comparison to 96.2% with the Excluder endoprostheses. Despite treatment outside of IFU,
the treatment modality in question appears to be effective in the primary purpose of preventing aneurysm
rupture and death. This is further reinforced by the high five-year freedom from sac rupture outlined in the
ENGAGE cohort (98.8%).

Despite the successful deployment of these endoprostheses in preventing aneurysm rupture, the rate of
reintervention in this analysis was relatively high (ENGAGE 16% vs. GREAT 15.5%). This has previously been
highlighted in the literature with reintervention-free survival estimated in one study to be 86% at three
years in those treated outside of IFU, as compared to 96% for those treated within [17]. A further endpoint
that is likely representative of the long-term complications following EVAR outside of IFU is the rate of la
endoleak development in this cohort (ENGAGE 10.6% vs. GREAT 7.0%). This is similar to previously
published data that estimated type Ia endoleaks as occurring in approximately 3.8%-15% of cases treated
outside of the IFU [18]. In response to the high rates of endoleaks and reintervention, further tools have been
promoted, including the utilization of endoanchors to assist in proximal stent stabilization. These have been
shown to successfully improve the sealing of abdominal endografts in cases of intraoperative type Ia
endoleaks in hostile neck anatomies [19]. However, further investigation is required to determine long-term
durability in cases where they have been utilized.

Limitations
There are some limitations to this analysis. First, it is a retrospective analysis of an amalgamation of
previously published data. However, the data in question (ENGAGE, GREAT) were collected prospectively on
an international scale, which provides this analysis with the power of a moderate multicentre study
representative of a real-world experience. Second, both ENGAGE and GREAT had a high number of patients
lost to follow-up. Once again, this is likely representative of everyday experience with patient factors
changing over time. Third, the variability in recorded endpoints between both registries somewhat limits the
applicability of these findings. This is highlighted by certain datasets such as endoleak only being recorded
in the GREAT registry if it resulted in reintervention. This likely results in an element of bias toward the
GREAT analysis.

Conclusions
Treatment outside of IFU has become increasingly more common with consistent advancements in
endograft technology. The increasingly aging and co-morbid population has also led to the promotion of this
trend. However, EVAR is fragile to late aortic changes, especially in hostile aortic neck anatomy, with a
propensity toward endoleak development and reintervention. This analysis reinforces the importance of the
consideration of either fenestrated or open repair in those aneurysms that fail to satisfy IFU while
endovascular repair in such a setting should be reserved as a last-resort strategy.

Additional Information
Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All
authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In
compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services
info: All authors have declared that no financial support was received from any organization for the
submitted work. Financial relationships: All authors have declared that they have no financial
relationships at present or within the previous three years with any organizations that might have an
interest in the submitted work. Other relationships: All authors have declared that there are no other
relationships or activities that could appear to have influenced the submitted work.

References

1. Parodi JC, Palma JC, Barone HD: Transfemoral intraluminal graft implantation for abdominal aortic
repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative
3. Prinssen M, Verhoeven EL, Bath J, et al.: A randomized trial comparing conventional and endovascular